Oryzon Genomics S.A. (0RDB.L)
EUR 2.68
(2.88%)
EUR 2.68
(2.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.55 Million USD | 451.85% |
| 2022 | 1.2 Million USD | 109.44% |
| 2021 | -12.75 Million USD | 59.96% |
| 2020 | -31.84 Million USD | -29.85% |
| 2019 | -24.52 Million USD | -33.04% |
| 2018 | -18.43 Million USD | -32.98% |
| 2017 | -13.86 Million USD | -1223.55% |
| 2016 | 1.23 Million USD | 110.93% |
| 2015 | -11.28 Million USD | -270.9% |
| 2014 | 6.6 Million USD | -47.78% |
| 2013 | 12.64 Million USD | 649.57% |
| 2012 | -2.3 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 8.47 Million USD | 0.0% |
| 2023 Q2 | 6.63 Million USD | 0.0% |
| 2023 Q4 | 6.55 Million USD | 0.0% |
| 2022 Q2 | -4.72 Million USD | 0.0% |
| 2022 Q4 | 1.28 Million USD | 0.0% |
| 2022 FY | 1.28 Million USD | 110.1% |
| 2021 Q4 | -12.75 Million USD | -131.89% |
| 2021 Q2 | -21.71 Million USD | 0.0% |
| 2021 Q3 | 39.99 Million USD | 284.17% |
| 2021 FY | -12.75 Million USD | 59.96% |
| 2020 Q4 | -31.84 Million USD | 9.38% |
| 2020 FY | -31.84 Million USD | -29.85% |
| 2020 Q1 | -20.24 Million USD | 17.48% |
| 2020 Q2 | -37.87 Million USD | -87.13% |
| 2020 Q3 | -35.14 Million USD | 7.22% |
| 2019 Q2 | -11.05 Million USD | 22.43% |
| 2019 Q1 | -14.24 Million USD | 22.72% |
| 2019 FY | -24.52 Million USD | -33.04% |
| 2019 Q4 | -24.52 Million USD | 11.12% |
| 2019 Q3 | -27.59 Million USD | -149.7% |
| 2018 Q2 | -7.39 Million USD | 33.0% |
| 2018 Q1 | -11.03 Million USD | 20.37% |
| 2018 FY | -18.43 Million USD | -32.98% |
| 2018 Q4 | -18.43 Million USD | -306.02% |
| 2018 Q3 | -4.54 Million USD | 38.61% |
| 2017 Q3 | -16.1 Million USD | 5.58% |
| 2017 Q1 | 6.13 Million USD | 397.29% |
| 2017 FY | -13.86 Million USD | -1223.55% |
| 2017 Q4 | -13.86 Million USD | 13.9% |
| 2017 Q2 | -17.05 Million USD | -377.93% |
| 2016 Q2 | -1.64 Million USD | 74.25% |
| 2016 FY | 1.23 Million USD | 110.93% |
| 2016 Q4 | 1.23 Million USD | 122.76% |
| 2016 Q3 | 553.91 Thousand USD | 133.65% |
| 2016 Q1 | -6.39 Million USD | 43.39% |
| 2015 Q1 | 9.96 Million USD | 50.81% |
| 2015 FY | -11.28 Million USD | -270.9% |
| 2015 Q4 | -11.28 Million USD | 0.0% |
| 2015 Q2 | 6.88 Million USD | -30.93% |
| 2014 Q3 | 6.88 Million USD | 0.0% |
| 2014 Q4 | 6.6 Million USD | -4.09% |
| 2014 Q1 | 2.8 Million USD | 0.0% |
| 2014 FY | 6.6 Million USD | -47.78% |
| 2013 FY | 12.64 Million USD | 649.57% |
| 2012 FY | -2.3 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | 110.865% |
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | 69.24% |
| Vetoquinol SA | -129.83 Million EUR | 105.049% |
| Valneva SE | 82.73 Million EUR | 92.076% |
| AB Science S.A. | 13.03 Million EUR | 49.705% |
| Nanobiotix S.A. | -29.8 Million EUR | 122.0% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | 2483.994% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 135.392% |
| BioSenic S.A. | 28.04 Million EUR | 76.623% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 103.337% |
| Formycon AG | 2.45 Million EUR | -167.482% |